Diazepam (DZ), the preferred anticonvulsant benzodiazepine (BZ) for the treatment of organophosphate (OP) nerve agent-induced seizures and neuronal damage has been associated with unwanted effects such as sedation, amnesia, cardio-respiratory depression, anticonvulsant tolerance, and dependence liability. In a search for safer and more effective anticonvulsant BZs against OP-induced seizure and neuronal damage, we have previously shown that imidazenil (IMD), a low intrinsic efficacy positive allosteric modulator of GABA action at α1-, which has high intrinsic efficacy at α2-, α3-and α5-containing GABA A receptors, is more potent and longer-lasting than diazepam pretreatment at protecting rats from diisopropyl fluorophosphate (DFP)-induced electrocorticographic (ECoG) seizures and neuronal damage. The effects of IMD were observed at doses that are devoid of sedative, amnestic, and anticonvulsant tolerance actions. In the present study, we compared the anticonvulsant and neuroprotective effects of a combination of atropine (2 mg/kg, ip) and 2-PAM (20 mg/kg, ip) with IMD (0.5 mg/kg, ip) or midazolam (MDZ, 0.5 to 2 mg/kg, ip) administered after the onset of DFP-(1.5 mg/kg, sc) induced seizure activity. The severity of DFP-induced ECoG seizures was assessed by continuous radio telemetry recordings in unrestrained and freely moving rats. Further, the extent of neuronal damage was evaluated using a neuron-specific nuclear protein (NeuN)-immunolabeling and fluoro-jade B (FJB) staining procedure. We report here that IMD is more efficacious and longer-lasting than sedating doses of MDZ in protecting rats from DFP-induced ECoG seizures and neuronal damage.
INTRODUCTION
In the wake of increased terrorist attacks around the globe, organophosphate (OP) nerve agents are a potential threat to civilians and military troops. The insidious use of these agents, e.g the 1995 Tokyo subway attack (Okumara et al., 2003) or the assaults during the Gulf War, left victims with long-term consequences even several years post exposure to these toxic agents Brix, 1998). The mechanisms underlying sustained epileptiform activity may be related to the increased activation of glutamatergic transmission and also to inactivation of GABA A receptor function (Chen and Wasterlain, 2006 ).
In the event of OP poisoning, conventional medical therapy includes combined administration of atropine sulfate (AT) to counteract acute muscarinic cholinergic crises, pralidoxime chloride (2-PAM) to reactivate inhibited AChE, and an anticonvulsant benzodiazepine (BZ) such as diazepam to increase GABA A receptor function to prevent brain seizures and subsequent neuronal damage McDonough and Shih, 1997) . The combination of AT and 2-PAM alone is used to counteract mild OP intoxication, but this combination is ineffective against moderate-to-severe intoxication, and the addition of an anticonvulsant BZ is necessary to control the progression of seizures into status epilepticus protecting rats from DFP-induced seizures and neuronal damage, the current study was designed to compare the protective efficacy of IMD to that of MDZ when administered after the onset of DFP-induced seizure activity. We therefore evaluated the effectiveness of a combination of AT and 2-PAM with a single dose of IMD or increasing doses of MDZ to protect rats from DFPinduced electrocorticographic (ECoG) seizure activity and brain neuronal damage. We show here that the administration of a combination of AT and 2-PAM with IMD is more efficacious than the combination AT and 2-PAM with MDZ at protecting rats from DFP-induced ECoG seizure activity and brain neuronal damage.
MATERIALS AND METHODS

Animals:
Adult male Fisher 344 rats (Harlan, Indianapolis) weighing 250-280 g were housed in groups (three per cage for histological studies) or individually (for radio telemetry) in standard plastic cages (42 cm x 26 cm x 20 cm) and maintained on an 11 to 13 hrs light/dark cycle (lights from 6:00 am to 7:00 pm). Standard rodent food and tap water were available ad libitum. All experiments were carried out in accordance with the National Institute of Health Guidelines for the Care and Use of Laboratory Animals as approved by the Animal Welfare Committee at the University of Illinois at Chicago.
Drugs:
Midazolam (MDZ) was a generous gift from Hoffman La-Roche (Basel, Switzerland).
Imidazenil (IMD) was obtained from Hoffman-La Roche (Nutley, NJ). Atropine sulfate (AT), pyridine-2-aldoxime methochloride (2-PAM) and diisopropyl fluorophosphate (DFP) were obtained from Sigma-Aldrich Co. (St. Louis, MO). AT and 2-PAM were dissolved in normal saline (0.9% NaCl). DFP supplied in oily solution was freshly diluted in ice-cold saline just prior to administration. MDZ or IMD was dissolved in 5-10% DMSO followed by dilution with vehicle that contained 11% polyethylene glycol-400, 50% propylene glycol, and 39% sterile water to a final DMSO concentration of < 0.5 % (Auta et al., 1995) . MDZ, IMD, AT, 2-PAM and vehicle were administered intraperitonially (ip). DFP was administered subcutaneously (sc) in volumes of 0.1 ml/100 g.
Surgical Implantation of Telemetry Probes
The severity and frequency of seizure activities were evaluated by continuous visual observation and radio telemetry recordings. All surgeries were performed under pentobarbital (50 mg/kg, ip) anesthesia using minor modifications of procedures described previously (Kramer Hair from the flat of the snout between the eyes and across the neck and abdominal area was shaved with a clipper. The skin was swabbed with povidone-iodine. The animal was then placed on a heating pad and a midline incision made from the bridge of the nose to the posterior of the cranium. An abdominal incision (approximately 2-cm) was also made through the linea Page 6 of 33  Toxicological Sciences   1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 by guest on November 4, 2016 http://toxsci.oxfordjournals.org/ Downloaded from alba and the underlying muscle wall along the ventral midline using a scalpel and scissors. The transmitter was placed in the peritoneal cavity and secured in position by suturing it to the inner surface of the abdominal wall using a non-absorbable nylon suture. The two cortical and muscle electrodes were threaded out of the abdominal wall and tunneled subcutaneously along the abdomen, over the shoulder, and through a 2-cm lateral incision made in the cranium and the abdominal skin was then sutured. The animal was positioned on a stereotaxis apparatus for electrode implantation. To ensure optimal placement of the EMG electrodes and to avoid electrocardiogram interference, leads were sutured bilaterally in the cervico-auricularis muscle (neck muscle) and the two ECoG cortical electrodes implanted supradurally in 1-mm circumference holes, each drilled 3-mm from the sagittal suture (midline) and 3-mm anterior to the lambdoid suture. The electrodes were anchored in to the skull using dental acrylic (Dentsply Caulk International, Milford, USA). After surgery, animals received a single dose of antibiotic (gentamycin, 5 mg/kg, im) and an analgesic (carprofen, 5 mg/kg, sc) within three hours of surgery; rats received additional doses of gentamycin and carprofen 24 hours after surgery.
Animals were allowed initial recovery under a heating lamp and were monitored until they regained a toe-pinch reflex, then were returned to their individual cages and left for a recovery period of 10 days prior to experimentation.
Drug treatment: After 10 days of recovery from probe implantation, rats were housed in individual cages and placed on radio telemetry receivers and a 60 min baseline EMG and ECoG activities recorded. After baseline recordings, rats received acute subcutaneous (sc) injections of a sub-lethal dose (1.5 mg/kg) of DFP freshly reconstituted in ice-cold saline and 2 min later a combination of AT (2 mg/kg, ip) and 2-PAM (20 mg/kg, ip). Ten minutes (time to onset of DFPinduced seizures) after DFP acute challenge separate groups of rats received a single dose of The neuronal nuclei antigen (NeuN) is a very specific protein that is highly expressed in differentiated neurons. Thus, we used NeuN immunohistochemistry to identify neuronal loss and to quantify total number of neurons in various rat brain areas.
Neuronal Damage
NeuN immunohistochemistry
Briefly, NeuN studies were carried out by washing free floating coronal sections (20 µm) 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 Analysis: Sections were examined using a Zeiss fluorescent microscope with a blue (450-490) excitation light by using the filter designed for visualizing fluorescein or FITC, which was suitable for fluoro-jade B staining. Fluorescent images were captured using an AxioVision 4.6 (Zeiss) and an AxioCam Camera for each brain area; five to six sections were taken and fluorescent-labeled cells were counted randomly with a bi-dimensional cell counting method at 40X objective in a square area of 100 x 100 µm. The final composites were processed using PowerPoint (Microsoft).
Statistical Analysis
The neuronal counts for FJB stain, NeuN, and power spectrum density analysis of ECoG recordings were analyzed using a one-way repeated analysis of variance (ANOVA) and post hoc analysis of variance was determined by the Duncan's test with multiple range comparison. The p values less than critical values .05 and .01 were considered statistically significant. 
RESULTS
Effects of imidazenil (IMD) or midazolam (MDZ) on DFP-induced seizures a) Behavioral Observations
Following acute DFP (1.5 mg/kg, sc) challenge and treatment with a combination of AT (2 mg/kg, ip) and 2-PAM (20 mg/kg, ip) ( Fig. 1) , the incidence of seizure activity which began 5 to 8 min post-DFP administration was 100%. Seizure activity was preceded by predictable and consistent behavioral signs including bouts of chewing activity and intermittent head tremors.
These behavioral signs were followed by whole body tremors, jerky motions, and Straub tail which rapidly progressed to explosive tonic-clonic motor convulsions, and finally into status epilepticus. Despite the severity of the seizure activity, the majority of rats (96 %) survived.
Seizure intensity and severity decreased over the next 8 to 24 h after acute DFP challenge.
The severity of seizure activity was reduced (absence of convulsive-like tremors, clonic jerks) in the first 30 min to 1 h in rats that received a combination including IMD (0.5 mg/kg, ip) or MDZ (1 or 2 mg/kg, ip) 10 min after DFP-acute challenge (Fig.1) . However, only IMD was still effective 3 h after DFP acute treatment. Moreover, rats that received IMD showed no noticeable signs of seizure activity 18 h after acute DFP challenge and appeared to have fully recovered 36 h after DFP treatment. In contrast, rats that received the combination with MDZ (2 mg/kg) exhibited body tremors, intermittent clonic jerks, dacryorrhea, and signs of respiratory distress 18 h after DPF treatment.
b) ECoG power spectra density analysis
In Fig. 2 we show 25 sec representative electrocorticographic (ECoG) traces and the corresponding electromyographic (EMG) activity recorded at baseline (panel A), 6 min after the 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 (Fig. 3) . However, at 5 and 30 min after IMD treatment, DFP-induced increases in power spectra density for δ, β1, and β2 frequencies were significantly attenuated. Except for the increase in power spectra density for the β2 frequency, IMD attenuation of DFP-induced increases in power spectra density for all three frequencies was sustained even by 180 min after IMD treatment. It is interesting to note here that IMD-induced attenuation of DFP-induced increases in power spectra density for the δ frequency was not only sustained over 180 min but the magnitude of this effect continue to decrease in a time-dependent manner after IMD acute challenge. In contrast to IMD, MDZ treatment was only effective against DFP-induced increase in the power spectra density for the δ frequency at 5 and 30 min after treatment. Moreover, the effect of MDZ on the δ frequency returned to DFP-induced levels at 180 min after MDZ treatment.
NeuN immuno-labeling:
To evaluate whether sustained DFP-induced seizure activity leads to neuronal damage, we used NeuN-immunolabelling, which has been used as biomarker for neuronal damage 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58 
DISCUSSION
A close association between sustained centrally-mediated ECoG seizure activity and brain neuropathologies that accompany exposure to OP agents has been well established In the present study, we show that a non-sedating dose of IMD provided a long-lasting and effective protection from DFP-induced seizure and neuronal damage whereas the protection by higher and sedating doses of MDZ was relatively moderate and short-lasting. Although at higher doses, MDZ elicited a rapid but short-lasting control of DFP-induced seizure activity, it fails to effectively protect rats from DFP-induced neuronal damage that occurs at a later time.
ECoG power spectral density analysis also shows that administration of IMD or MDZ attenuated 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 DFP-mediated increases in power spectra density for the delta (δ) frequency at 5 and 30 min after DFP-acute challenge. However, the attenuation of the δ frequency by IMD but not MDZ lasted beyond 180 minutes.
It is widely accepted that the neuropathological consequences of OP-poisoning is related to the severity and duration of seizure activity (Weinbroum, 2004; Lallement et al., 1998) . In addition, the concurrent and sustained changes in relative power spectra density for the δ frequency that occur during prolonged seizure-activity have been correlated with the neuropathological changes that occur in the brain during OP-poisoning (Carpentier et al., 2001 ).
Thus, one can surmise that the differences in the effectiveness of these BZs in attenuating DFPinduced neuronal damage may be due to differences in the duration of action in suppressing DFP-induced increases in the relative power spectra density for the δ frequency. These differences could also be related to the differences in the pharmacokinetic properties of IMD and MDZ. MDZ is less efficacious than IMD, most likely because of its relatively short duration of action in suppressing the propagation of DFP-induced seizure activity. This view is supported by evidence suggesting that continued limbic seizures lasting for about 1 h produce moderate brain damage; whereas 3 to 4 h of status epilepticus induces extensive brain damage (Lemos and Cavalhiero, 1995; Fujikawa, 1996) . Thus, the preferred anticonvulsant agent for cases of OPpoisoning must not only possess a fast onset and prolonged duration of action but also should be devoid of unwanted side effects including sedation, amnesia, cardio-respiratory depression, and 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 
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